StockwhizBeta
← Startup News
Funding round
Healthcare

Commit Biologics Raises $60 million Seed to Take COM002 Into the Clinic and Expand Its Pipeline

Stockwhiz
0 views
Commit Biologics

Commit Biologics completed a $60 million (€54 million) seed financing round, with the final close led by Ackermans & van Haaren and participation from AbbVie Ventures, M Ventures, Bioqube Ventures, Korys and Novo Holdings. The financing will take COM002 toward the clinic, advance a second program into IND-enabling development and expand its BiCE™ pipeline.

At a Glance

Commit Biologics

DenmarkHealthcare
Raised
$60 million
Round
seed
Investors
6
Investors
Ackermans & van HaarenAbbVie VenturesM VenturesBioqube VenturesKorysNovo Holdings
Target market
Patients with cancer and autoimmune disease
Use of funds
Supporting completion of IND-enabling activities and IND filing for COM002 to take it into the clinic, advancing a second program into IND-enabling development and expanding the BiCE™ pipeline

Key people

  • Dr. Thomas L. F. Montgomery Andresen

    CEO

  • Mikael B. L. Winkler

    Co-founder & Head of Platform Technology

Get started

Create a free account to read the full story.

Sign Up

Already have an account? Log in

Quick Answers

What is the latest news about Commit Biologics?

Commit Biologics completed a $60 million (€54 million) seed financing round, with the final close led by Ackermans & van Haaren and participation from AbbVie Ventures, M Ventures, Bioqube Ventures, Korys and Novo Holdings. The financing will take COM002 toward the clinic, advance a second program into IND-enabling development and expand its BiCE™ pipeline.

What does Commit Biologics do?

Commit Biologics is a biotechnology company developing complement-powered immune engagers. Its BiCE™ approach is designed to direct the complement system against diseased cells, with development focused on cancer and autoimmune disease.

How much did Commit Biologics raise?

Commit Biologics raised $60 million in its seed.

Who invested in Commit Biologics?

Investors named in this seed include Ackermans & van Haaren, AbbVie Ventures, M Ventures, Bioqube Ventures, Korys and Novo Holdings.

How will Commit Biologics use the funding?

Commit Biologics plans to use the money for supporting completion of IND-enabling activities and IND filing for COM002 to take it into the clinic, advancing a second program into IND-enabling development and expanding the BiCE™ pipeline.

Where is Commit Biologics based?

Commit Biologics is based in Denmark.

Who are the key people at Commit Biologics?

Key people named in this report: Dr. Thomas L. F. Montgomery Andresen (CEO) and Mikael B. L. Winkler (Co-founder & Head of Platform Technology).